ID   MCF-7/164R-4
AC   CVCL_1D49
SY   MCF7/164R-4; 164R-4
DR   cancercelllines; CVCL_1D49
DR   CancerTools; 152101
DR   ECACC; 16022503
DR   Wikidata; Q54904339
DR   Ximbio; 152101
RX   PubMed=7759159;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:31638; Fulvestrant (ICI 182780).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): ECACC
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 11
ST   D16S539: 11,12
ST   D18S51: 14
ST   D21S11: 30
ST   D3S1358: 16
ST   D5S818: 11,12
ST   D7S820: 8,9
ST   D8S1179: 10,14
ST   FGA: 23,25
ST   Penta D: 12
ST   Penta E: 7,12
ST   TH01: 6
ST   TPOX: 9,12
ST   vWA: 14,15
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1D47 ! MCF-7/S0.5
SX   Female
AG   69Y
CA   Cancer cell line
DT   Created: 08-07-15; Last updated: 05-10-23; Version: 16
//
RX   PubMed=7759159; DOI=10.1002/ijc.2910610417;
RA   Lykkesfeldt A.E., Larsen S.S., Briand P.;
RT   "Human breast cancer cell lines resistant to pure anti-estrogens are
RT   sensitive to tamoxifen treatment.";
RL   Int. J. Cancer 61:529-534(1995).
//